91 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.
Harvard University
Discovery ofa-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Dongguk University
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Baylor College of Medicine
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Baylor College of Medicine
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Baylor College of Medicine
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
TBA
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
Chinese Academy of Sciences
Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
University of Oxford
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Novartis Institutes For Biomedical Research
Accelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions.
Atavistik Bio
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.
Merck
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1.
Shenyang Pharmaceutical University
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
University of Manchester
Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
Shandong Provincial Hospital Affiliated To Shandong University
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
Guizhou Medcial University
Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Chinese Academy of Sciences
Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
Huazhong Agricultural University
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Forma Therapeutics
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.
Meyer Cancer Center
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Agios Pharmaceuticals
Flavipesines A and B and Asperchalasines E-H: Cytochalasans and Merocytochalasans from
Huazhong University of Science and Technology
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Zhejiang University
Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Shanghai Haihe Pharmaceutical
Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.
TBA
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Forma Therapeutics
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
China Pharmaceutical University
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Agios Pharmaceuticals
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Novartis Institutes For Biomedical Research
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
China Pharmaceutical University
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Shanghai Haihe
Lucky Switcheroo: Dramatic Potency and Selectivity Improvement of Imidazoline Inhibitors of Human Carbonic Anhydrase VII.
Saint Petersburg State University
Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).
National Center For Advancing Translational Sciences
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
Iridinesulfonamide compound and use method thereof
Chia Tai Tianqing Pharmaceutical Group
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Eli Lilly
Compound having mutant IDH inhibitory activity, preparation method and use thereof
Shanghai Haihe Pharmaceutical
Methods and compositions for cell-proliferation-related disorders
Agios Pharmaceuticals
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H
Bayer Pharma Aktiengesellschaft
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Forma Tm2
Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
Sunshine Lake Pharma
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Forma Tm2
Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
Agios Pharmaceuticals
2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
Bayer Pharma Aktiengesellschaft
Heterocyclic derivatives and their use in the treatment of neurological disorders
Novartis
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
National Institutes of Health
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Albert Einstein College of Medicine